Health

AmorSui Upgrades Protective Product Line In Effort To Set ‘New Standard’ In Health Care

May 10, 2024

A South Philadelphia apparel company launched during the Covid-19 pandemic has unveiled its improved and enhanced line of personal protective equipment (PPE) for health care workers and others. AmorSui was launched in 2020 by Beau Wangtrakuldee, a scientist and entrepreneur who founded the company after a chemical spill in a lab left her with severe burns. […]

Read More

Latus Launches with State-of-the-Art Gene Therapy Development Technologies, Two Lead Product Candidates, and an Initial $54 Million in Series A Financing

May 6, 2024

Latus Bio, Inc. (“Latus”), a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), today announced its launch and an initial close of $54 million in Series A financing. The funding round is being led by 8VC and DCVC Bio. To date, Samsung Life Science Fund (created by Samsung […]

Read More

Philadelphia Sits Among Nation’s Elite Life Sciences Hubs In New Colliers Rankings

April 30, 2024

The Philadelphia region takes fourth place in a new ranking of the country’s top life sciences hubs on the strength of its talent pipeline and recent real estate activity. The analysis conducted by the commercial real estate services firm Colliers International focuses on a region’s ability to support and sustain industry growth using factors such […]

Read More

Cagent Vascular Raises $30 Million Series C Financing

February 22, 2024

Funds will be used to accelerate US market adoption and to expand the product portfolio of the first and only Serration Angioplasty Technology Cagent Vascular, Inc., a rapidly growing commercial stage medical device company, today announced a Series C Financing close in excess of $30M. U.S. Venture Partners (USVP), led the round. Participation included new […]

Read More

Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma

December 7, 2023

Vittoria Biotherapeutics has announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). For the initiation of a first-in-human Phase 1 clinical trial to evaluate the Company’s lead candidate, VIPER-101, a gene-edited, autologous, CAR-T cell therapy for treatment of patients with relapsed or refractory T-cell lymphoma. “The […]

Read More

SAIL Fusion Announces First Implantations Of Its BowTie™ Sacroiliac Fusion System

October 18, 2023

SAIL Fusion, a medical device company focused on advancing the surgical treatment of sacroiliac joint dysfunction through solutions built upon AO principles, today announced that it has conducted the first implantations of its novel BowTie SI Fusion System. The surgeries began on October 14th and were conducted by Dr. Peter Whang, Associate Professor of Orthopaedics […]

Read More

Astarte Medical And Tiny Health Join Forces To Optimize Gut Health For Vulnerable Preterm Infants

September 21, 2023

The new partnership will seek to develop an end-to-end NICU solution to stratify and treat at-risk babies. Astarte Medical, a leading pediatric clinical intelligence company, is forming a joint venture with Tiny Health, makers of gut microbiome tests for babies and expecting parents. The partners have agreed to develop a clinical-facing technology solution to support gut […]

Read More

Nobias Therapeutics Announces Acceptance Of Late-Breaking Abstract

September 20, 2023

Nobias Therapeutics, a biotechnology company pioneering AI-based deep phenotyping techniques to discover advanced therapeutics, today announced new results. From a Phase 2 clinical trial of NB-001 (fasoracetam) for the treatment of the neuropsychiatric symptoms associated with 22q11.2 deletion syndrome (“22q11DS”) in children have been selected for a poster presentation at the 52nd Child Neurology Society […]

Read More

Advent Therapeutics Awarded $3 Million NIH Grant For Novel Neonatal Lung Therapy

July 20, 2023

Advent Therapeutics, Inc., a biotechnology company pioneering an optimized retinol palmitate (vitamin A) drug product as a breakthrough non-invasive inhaled neonatal lung therapy, has been awarded a $3 million National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Phase IIB grant. This grant allows the Company to position its novel aerosolized vitamin A formulation […]

Read More

Cagent Vascular Announces Initial RECOIL Study Results: Serranator Demonstrates 49% Less Recoil Than POBA In BTK Arteries

July 19, 2023

Cagent Vascular, the exclusive developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its Below-the-Knee (BTK) RECOIL study. This Core Lab-Adjudicated Recoil analysis, the first of its kind, evaluated vessel recoil in lesions treated with Serranator® verses Plain Old Balloon Angioplasty (POBA). The study results demonstrated that lesions treated using […]

Read More

Next